Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis.

J Ovarian Res · 2026 · PMC12924399 · PMID 41593690

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The addition of durvalumab without olaparib (DBC) showed a favorable trend toward improved survival, albeit without statistical significance [ 9 ].

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.